258 related articles for article (PubMed ID: 32908231)
1. Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma.
Patel KS; Yao J; Raymond C; Yong W; Everson R; Liau LM; Nathanson D; Kornblum H; Wang C; Oughourlian T; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
Sci Rep; 2020 Sep; 10(1):14819. PubMed ID: 32908231
[TBL] [Abstract][Full Text] [Related]
2. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
[TBL] [Abstract][Full Text] [Related]
3. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
Ellingson BM; Gerstner ER; Smits M; Huang RY; Colen R; Abrey LE; Aftab DT; Schwab GM; Hessel C; Harris RJ; Chakhoyan A; Gahrmann R; Pope WB; Leu K; Raymond C; Woodworth DC; de Groot J; Wen PY; Batchelor TT; van den Bent MJ; Cloughesy TF
Clin Cancer Res; 2017 Oct; 23(19):5745-5756. PubMed ID: 28655794
[No Abstract] [Full Text] [Related]
4. Low perfusion compartments in glioblastoma quantified by advanced magnetic resonance imaging and correlated with patient survival.
Li C; Yan JL; Torheim T; McLean MA; Boonzaier NR; Zou J; Huang Y; Yuan J; van Dijken BRJ; Matys T; Markowetz F; Price SJ
Radiother Oncol; 2019 May; 134():17-24. PubMed ID: 31005212
[TBL] [Abstract][Full Text] [Related]
5. Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma.
Kondo M; Uchiyama Y
J Neuroradiol; 2018 Jul; 45(4):236-241. PubMed ID: 29274693
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis.
Kurokawa R; Baba A; Kurokawa M; Capizzano A; Hassan O; Johnson T; Ota Y; Kim J; Hagiwara A; Moritani T; Srinivasan A
AJNR Am J Neuroradiol; 2022 Feb; 43(2):202-206. PubMed ID: 35058300
[TBL] [Abstract][Full Text] [Related]
7. Decorin in human oral cancer: a promising predictive biomarker of S-1 neoadjuvant chemosensitivity.
Kasamatsu A; Uzawa K; Minakawa Y; Ishige S; Kasama H; Endo-Sakamoto Y; Ogawara K; Shiiba M; Takiguchi Y; Tanzawa H
Biochem Biophys Res Commun; 2015 Jan; 457(1):71-6. PubMed ID: 25550184
[TBL] [Abstract][Full Text] [Related]
8. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
9. Apparent Diffusion Coefficient as a Predictive Biomarker for Survival in Patients with Treatment-Naive Glioblastoma Using Quantitative Multiparametric Magnetic Resonance Profiling.
Kim BS; Kim ST; Kim JH; Seol HJ; Nam DH; Shin HJ; Lee JI; Kong DS
World Neurosurg; 2019 Feb; 122():e812-e820. PubMed ID: 30391622
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
Jajamovich GH; Valiathan CR; Cristescu R; Somayajula S
J Neurooncol; 2016 Sep; 129(2):289-300. PubMed ID: 27393347
[TBL] [Abstract][Full Text] [Related]
11. Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement.
Cho N; Wang C; Raymond C; Kaprealian T; Ji M; Salamon N; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
J Neurooncol; 2020 May; 147(3):643-652. PubMed ID: 32239430
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
[TBL] [Abstract][Full Text] [Related]
13. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
14. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
[TBL] [Abstract][Full Text] [Related]
15. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
[TBL] [Abstract][Full Text] [Related]
16. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
[TBL] [Abstract][Full Text] [Related]
17. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
18. Correlation analysis of expressions of PTEN and p53 with the value obtained by magnetic resonance spectroscopy and apparent diffusion coefficient in the tumor and the tumor-adjacent area in magnetic resonance imaging for glioblastoma.
Li Y; Ji F; Jiang Y; Zhao T; Xu C
J BUON; 2018; 23(2):391-397. PubMed ID: 29745082
[TBL] [Abstract][Full Text] [Related]
19. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
20. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.
Chang W; Pope WB; Harris RJ; Hardy AJ; Leu K; Mody RR; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
Tomography; 2015 Sep; 1(1):37-43. PubMed ID: 26740971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
